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Abstract
Colorectal cancer is one of the most common cancers in the world. Histoclinical staging is efficient, but combi-
nation with molecular markers may improve the classification of stage II cancers. Several tumor-suppressor genes
have been associated with colorectal cancer, and the most frequent allelic losses have been extensively studied for
their prognosis effect, but the results remain controversial. In a previous study, we found a possible influence of the
chromosome 5 status in the development of liver metastases in stage II colon cancers. We have here investigated the
role of the APC gene, located in chromosome arm 5q, in a series of 183 colon adenocarcinomas through a combined
analysis of gene expression, mutation, allelic loss and promoter methylation, and metastasis occurrence. Point muta-
tions were found in 73% of cases and allelic losses were found in 39%; 59% of tumors presented with a biallelic in-
activation, with a very strong interdependence of the two APC hits (P=2.1× 10−9). No associationwas found between
expression, number and type of APC alterations, and metastatic evolution. Our results show that the determination of
APC status cannot help in the prediction of metastasis and cannot be used to subclassify stage II colon cancers.
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Introduction
APC is often cited as a prime example of a tumor-suppressor gene.
Germline mutations occur in familial adenomatous polyposis (FAP)
and somatic mutations in tumors of the digestive tract [1]. Most of
the mutations occur within the first half of the coding sequence and
result in the truncation of the APC gene product. Somatic mutations
in colorectal tumors are clustered in a particular region called the mu-
tation cluster region (MCR) [2]. Inactivation of both alleles of the
APC gene is required as an early event to develop most of adenomas
and carcinomas in the colon and rectum [3]. In sporadic microsatellite
stable tumors (MSSs), the second hit at the APC locus consists in either
loss of heterozygosity (LOH) or a second mutation, each in roughly
40% of the cases [4]. Promoter methylation has been proposed as an
alternative to mutation or LOH also leading to gene inactivation [5]. In
FAP, the second APC hit is determined by the site of the first germline
event [6,7].
Studies of somatic APC inactivation in sporadic colorectal carcinomas
confirmed and reinforced the two-hit interdependence theory [8–10].
The preferred explanation is that APC somatic mutations are selected
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according to a specific level of β-catenin signaling that induces tumor
formation [11]. Because allelic losses have been identified in tumors
exhibiting two APC somatic mutations [12,13], a new theory progres-
sively emerged, that is, tumor severity unusually requires three APC hits
instead of two and that the most frequent third hit was copy number
gain or deletion [14,15]. If tumors develop and progress through step-
wise accumulation of mutations in different functional pathways, with
APC, it also seems that repeated targeting of the same pathway and/or
gene is selected in some cancers.
Colorectal cancer is associated with therapeutic challenges. Half of
the patients die within 5 years after diagnosis despite regular progress
in adjuvant chemotherapy protocols and the use of targeted drugs.
To date, it is not recommended to enter systematically stage II colo-
rectal cancer patients (30% of cases) in adjuvant chemotherapy pro-
tocols, although more than 20% will develop distant metastases. The
monitoring of genetic alterations could provide independent prog-
nostic information, but frequent discrepancies have limited their
use in medical practice.
In a previous study, we showed that metastatic risk in stage II
colon adenocarcinomas increased 3.4-fold when both chromosome
5q arms were retained [16]. To determine what type of 5q and
APC gene alteration could influence clinical evolution, we studied
an independent series of 183 stage II colon adenocarcinomas com-
bining clinical, genomic, and expression profiles.
Materials and Methods
Ethic Statements
The institutional review board (COS, Comité d’Orientation
Stratégique) approved the project in September 27, 2007. A total
of 183 colon cancer patients were enrolled in the study. Inclusions
ended November 5, 2008. All patients signed a written informed
consent to authorize further research studies on their tumor material
before storage in the respective biological resources centers.
Patients and Biological Samples
Clinical data and biologic samples were provided by the members
of the CIT3 program (colon cancer identity card) driven by a national
consortium in France. Patients were selected through the different
projects developed by the five consortium teams for having been di-
agnosed with sporadic colon adenocarcinomas classified as stage II
and of MSS type at primary surgery. The MSS status was assessed
by multiplex polymerase chain reaction (PCR) genotyping using
the MSI Analysis System v1.2 (Promega, Charbonnières, France).
Disease-free patients were followed up for a minimum of 36 months
after surgery, and the occurrence of liver metastasis within the interval
was recorded.
Tissue samples were collected on fresh surgical specimens by
pathologists within 1 hour after surgery from patients who under-
went curative colonic resection, then flash frozen in liquid nitrogen,
and stored at −80°C until nucleic acids extraction. Nucleic acids were
extracted using QIAamp and RNeasy kits (Qiagen, Courtaboeuf,
France) according to the manufacturer’s instructions. Quantification
of samples was done with a NanoDrop ND-1000 spectrophotom-
eter (Thermo Fisher Scientific, Illkirch, France). RNA integrity
was controlled on an Agilent Bioanalyzer (Agilent Technologies,
Massy, France).
APC, KRAS, and BRAF Alterations Detection
The APC (exons 3 to 15 part J) [17], KRAS (exon 2), and BRAF
(exon 15) genes were analyzed by direct sequencing of after PCR
amplification. The presence of mutations was scored using the
PhrepPhrapConsed v11 package then encoded according to the
HGVS recommendations.
The allelic status of the APC locus was derived from comparative
genomic hybridization analyses performed on 44K BAC arrays and
scored after normalization with comparative genomic hybridization
Analytics v2.4 software (Agilent technologies, Massy France). It was
systematically checked by genotyping of the microsatellite locus
D5S346 using fluorescent primers.
The methylation status of the APC promoter was determined
using a pyrosequencing technique. The analysis was restricted to
the 1A region known as the major APC promoter [18]. Zymo EZ
Methylation Direct kit was used for bisulfite conversion according to
the manufacturer’s recommendations (Zymo Research Corp, Orange,
CA). Modified DNA was amplified by PCR with primers 5′TTG-
TTTGTTGGGGATTGG and 5′biotin TCCAACACCTACCC-
CATTTC for 45 cycles at an annealing temperature of 56°C. The
biotinylated strand was isolated using a Vacuum Prep Tool (Qiagen, Inc,
Valencia, CA) according to the manufacturer’s protocol. Pyrosequencing
reactions were performed using a PyroMark Q96 MD Pyrosequencing
instrument (Qiagen, Inc) with 500 nM of sequencing primer 5′GAGA-
GAAGTAGTTGTGTAAT that allowed the quantification of the
methylation proportion of seven CpG. The global methylation level
was calculated as the mean of each individual value.
Gene Expression Profiling
Expression profiles were established with Affymetrix U133 Plus 2.0
human oligonucleotide microarrays [19]. Scanning was done with an
Affymetrix GeneArray scanner and quantification with the Affymetrix
GeneChip Operating Software (Affymetrix, Paris, France). CEL files
were processed in the R/Bioconductor environment. Preprocessing
steps (background adjustment, normalization, and summarization)
were performed with the GCRMA package [20]. Expression measures
were handled on log2 scale for statistical computations as well as for
display purposes. Genes with overall low intensity were removed from
further analysis. All remaining genes had an expression value greater
than log2 (100) in at least 10% of the samples. As tumor samples and/or
RNA samples were provided by four different centers (Bordeaux,
Marseille, Nice, and Paris AP-HP), genes were then median centered
within each center individually. Data from the single sample from
Nantes were pooled with that of the smallest group, that is, Paris
AP-HP. Hierarchical clustering analyses were done with the R’s hclust
function. Genes and arrays dissimilarity matrices were computed using
Pearson correlation and Euclidian distance, respectively. Both trees
were built with Ward’s linkage. Supervised analyses were done in the
R/Bioconductor environment using the Limma moderated t test [21].
Nominal P values were adjusted with the Benjamini-Hochberg method
controlling the false discovery rate.
Results
Biallelic APC Inactivation
A total of 184 DNA were screened for APC mutations and allelic
loss. Analysis was not complete because of insufficient quantity or bad
quality of DNA in 31 cases, which were no longer considered. A total of
59 losses of the long arm of chromosome 5 (5q LOH), 154 truncating
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mutations, and 1 APC microdeletion were detected. No alteration was
evidenced in 29 samples. Single allelic loss or mutation was found in
12 and 22 samples, respectively. Two mutations were recorded in
43 tumors and 47 cases exhibited one mutation and one allelic loss;
thus, 90 tumors showed two hits at the APC locus (TableW1). Accord-
ing to the position of the seven β-catenin degradation sites starting at
codon 1265, the nature of the two hits was analyzed and revealed a
highly specific spectrum (Table 1; P = 2.1 × 10−9).
Relationship between APC Status and Expression Profile
Expression profiles of 86 samples from the COL2 project (Table W2)
were available to examine correlations with the APC status. In this series,
46 samples exhibited two hits at the APC locus. To explore the contri-
bution of the APC promoter methylation to global APC inactivation,
the methylation level was determined in the remaining 40 samples.
Methylation values ranged from 1% to 69%. Because negative controls
did not exceed 2%, tumors were scored unmethylated when the value
was in this range (16 samples); 14 samples exhibited a methylation level
greater than 10% and were thus considered as methylated; 10 samples
had a value between 2% and 3.3% and were considered as unmethy-
lated. Considering methylation as an APC inactivation mode, 13 tumors
showed complete APC inactivation: 11 with a mutation and 2 with a
5q allelic loss solely.
Unsupervised hierarchical clustering done after normalization
(GEO access number GSE26905) showed no clear evidence that APC
status could play a key role in shaping the expression profiles (Figure 1).
To address more specific issues, several supervised analyses were done.
They included the presence or absence of 5q LOH (25 vs 61 cases), of
at least one APCmutation (68 vs 18 cases), of one APC alteration, that
is, 5q LOH or APC mutation (73 vs 13 cases), the position of at least
one APC mutation before or after codon 1265 (38 vs 30 cases), and,
finally, the APC inactivation mode in case of two hits (25 samples with
two APC mutations vs 21 cases with one APC mutation + one 5q
LOH). None of them did generate a discriminating genes list signifi-
cant enough to enable further investigation. When considering the
methylation status, complete APC inactivation was found in 59 tumors,
but their expression profile did not differ from that of tumors without
APC alteration (13 cases).
Expression Profile and Metastases Occurrence
The 86 patients whose tumor expression profile was available were
diagnosed at a mean age of 66.5 years (range = 31-94 years). They
Figure 1. Hierarchical clustering of 86 stage II colon adenocarcinomas of MSS type. Unsupervised analysis was done on the 86 RNA
selected according to the inclusion criteria (stage II, colon, MSS type) within tumor samples of the COL2 project (Table W2). Tumors
from different origins were equally distributed within the different branches (top of the clustering): 32 from Bordeaux (BER, black), 28
from Nice (CAL, orange), 19 from Marseille (IPC, cyan), 6 from Paris AP-HP (3 from Lariboisière hospital [LAR, green] and 3 from Saint-
Antoine hospital [STA, brown]), and 1 from Nantes (NAN, yellow). The occurrence (black) or not (white) of distant metastases is given at
the bottom followed by the APC status. Mutations are presented in pink or light brown if occurring before or after codon 1265, respectively;
dark pink shows mutations leading before the β-catenin–binding domain starting at codon 1020.
Table 1. APC Inactivation Mode in Tumors with Two Hits.
Hits Mutation
<Codon 1265 >Codon 1265
LOH 14 33
Mutation <Codon 1265 0 39
>Codon 1265 −(39) 4
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were 42 men and 44 women, with a tumor localized in the ascending
or descending colon in 22 and 64 cases, respectively. None of them
received adjuvant chemotherapy. Twenty-one developed liver metas-
tasis within 36 months after diagnosis. The others were disease free at
this end point. Expression profiles depending on the presence or
absence of distant metastasis were not associated with selective pat-
terns. KRAS and BRAF mutations did not discriminate any subgroup
according to the disease evolution.
Discussion
Allelic loss on chromosome arm 5q was found in 39% of 153 stage II
colon adenocarcinomas of MSS type. This proportion is comparable
to that found in other studies including the initial full description
[22]. At least one mutation of the APC gene was observed in 73%
of tumors, being concentrated in the MCR for 62% as expected
[2]. Biallelic inactivation was found in 59% of cases, equally distrib-
uted in a combination of one APCmutation plus one 5q allelic loss or
two APC mutations. This frequency is slightly lower than that previ-
ously reported, as well as the proportion of tumors harboring one APC
mutation and 5q LOH [8,23]. The preferential association of muta-
tions occurring in the MCR with 5q allelic loss reinforces the theory
of the two-hit interdependence observed in sporadic colorectal cancers
as well as in FAP-derived cancers.
No difference in expression profiles was observed when comparing
biallelic inactivation modes. The most probable explanation is that
RNA predicted to encode a much-shortened protein is unstable. This
decreased stability has been shown to preclude protein truncation
tests for the detection of mutations leading the first 14 exons of the
APC gene [24,25]. Non–sense-mediated messenger RNA (mRNA)
decay might hide here the possible differences between cells with
biallelic inactivation due to one APCmutation before the MCR (with
subsequent non–sense-mediated mRNA decay) plus one within the
MCR or one mutation within the MCR plus one 5q allelic loss (with
no mRNA at all). Proteins resulting from APC mutations should thus
lead in both situations to half protein dosage in tumor cells com-
pared to normal cells and to the conservation of APC ability to
bind β-catenin. This observation suggests that a residual activity
of β-catenin binding is probably necessary for tumor growth [11].
A more surprising observation was that no difference exists be-
tween tumors exhibiting at least one APC alteration (APC mutation
and/or 5q allelic loss and/or APC promoter methylation) or none.
Among 86 expression profiles available to analyze this parameter, only
13 were derived from tumors with no APC alteration, a proportion
that probably is too low to document such effects; furthermore, this
group of “no-mutation” cases is a fortiori not big enough to look at
differences if we hypothesize that part of them have missed APC
mutations and a part developed through a β-catenin–independent
mechanism. This issue could be partially resolved by analyzing the
APC protein expression, but formalin-fixed tissues were generally
not available for this series of tumors.
Twenty-one patients developed distant metastases, that is, 24% of
cases, an expected proportion in stage II colon adenocarcinomas. We
were not able to detect differences in expression profiles between the
groups with and without metastases. Tumor cells studied were part
of primary lesions that did not metastasize in lymph nodes at the
initial resection. It is possible that this type of sample is poor in cells
prone to expand in a distant host organ through blood invasion sev-
eral years later. Global analysis of the primary tumor is thus unable to
detect their specific characteristics. An efficient option would be to
compare primary tumors from 3-year disease-free patients and meta-
static samples from patients with metastases at diagnosis.
In summary, our study shows that, although the APC gene seems
to play a central role in primary tumor formation through a fine reg-
ulation of the β-catenin pathway, it is probably not directly or mainly
involved in the metastatic process.
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